Mineralys Therapeutics had its Relative Strength (RS) Rating upgraded from 88 to 92 Wednesday.
IBD's unique RS Rating measures technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the best stocks tend to have an RS Rating of over 80 in the early stages of their moves.
Here Are 3 Keys For Successful Stock Investing
Mineralys Therapeutics has climbed more than 5% past a 15.25 entry in a first-stage consolidation, meaning it's now out of a proper buy range. Look for the stock to offer a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week line.
Mineralys Therapeutics showed 0% EPS growth last quarter, while sales growth came in at 0%.
The company holds the No. 107 rank among its peers in the Medical-Biomed/Biotech industry group. Krystal Biotech, ADMA Biologics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
